CAMBRIDGE, Mass., March 7, 2017 /PRNewswire-iReach/ -- rHEALTH LLC, a digital health solutions company and a spin-off of DNA Medicine Institute Inc., today announced that they have an ongoing agreement with Bioverativ Inc., a global biotechnology company focused on rare blood disorders.
“We are excited to continue this collaboration with Bioverativ to implement our unique diagnostic technology that may advance the use of the rHEALTH platform,” stated Dr. Eugene Chan, President and CEO.
As part of the collaboration, rHEALTH will conduct research on a coagulation assay using its rHEALTH diagnostic platform.
About rHEALTH
rHEALTH is a digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.
Media Contact:Lillian Li, rHEALTH, LLC, (617) 913-7630, pr@rhealth.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE rHEALTH LLC
